Tag Archives: Enzo Biochem

April 2024—Enzo Biochem announced it has entered into an agreement in which Labcorp will acquire the assets of Enzo’s clinical laboratory division, Enzo Clinical Labs. Labcorp said the acquistion will bolster its commitment to the New York tristate health care communities. Completion of the sale is contingent on approval by Enzo’s shareholders and other customary closing conditions.  

March 20, 2023—Enzo Biochem announced it has entered into an agreement in which Labcorp will acquire the assets of its clinical laboratory division, Enzo Clinical Labs.

May 28, 2020—Enzo Biochem announced it is offering a SARS-CoV-2 IgG ELISA assay kit for serological detection of IgG antibodies against the novel coronavirus under the FDA’s emergency use authorization.

July 2015—Enzo’s TIMP-1 ELISA kit is designed to provide a useful tool for investigating the TIMP-1 levels in multiple human matrices and aims to advance the studies on TIMP-1 function. The assay format allows for quantitative detection of 30 pg/mL of TIMP-1 in various sample types including serum, plasma, saliva, urine, and tissue culture media.

June 2015—Enzo Biochem announced the development of the FlowScript assay in detection of messenger RNA from HPV oncogenes E6 and E7. The FlowScript technology platform is a proprietary flow-cytometry-based molecular detection system for the multiplex analysis of cell function and identity; the HPV E6/E7 assay is the first product to use this novel platform.

May 2015—Enzo Biochem announced the development of the FlowScript assay in detection of messenger RNA from HPV oncogenes E6 and E7. The FlowScript technology platform is a proprietary flow-cytometry-based molecular detection system for the multiplex analysis of cell function and identity; the HPV E6/E7 assay is the first product to use this novel platform. Analysis is performed on a small volume of a liquid cytology specimen and can be incorporated as a reflex test measure following abnormal Pap smear results.